Tags : ArQule

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

Merck to Acquire ArQule for $2.7B

Shots: Merck to acquire Arqule in all-cash transactions at $20/share, making a total deal value $2.7B. The transaction is expected to be completed in Q1’20 The focus of the acquisition is to bolster Merck’s oncology pipeline with the addition of ArQule’s lead investigational candidate, ARQ 531, a precision therapy to treat hematological malignancies ArQule’s ARQ […]Read More